Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PALISADE BIO, INC.

Get SEC filing alerts via email and in your feed for PALISADE BIO, INC.

PALI

PALISADE BIO, INC.

About PALISADE BIO, INC.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead candidate, PALI-2108, targets inflammatory bowel disease (IBD), including ulcerative colitis and fibrostenotic Crohn’s disease, using a localized PDE4 inhibitor prodrug approach. The company focuses on precision medicine, strategic collaborations, and advancing drug candidates through clinical trials to address unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PALISADE BIO, INC.

1
1
PALISADE BIO, INC. Palisade Bio Reports Increased Financial Losses and Strong Cash Position in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
PALISADE BIO, INC. Palisade Bio Reports $18.1 Million Operating Loss, Secures $127.6 Million from Public Offering

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PALISADE BIO, INC. Palisade Bio Reports $2.87 Million Net Loss in Q3 2025, Sees Decrease in Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PALISADE BIO, INC. Palisade Bio Reports $2.8 Million Net Loss for Q2 2025, 32% Improvement Year-Over-Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PALISADE BIO, INC. Palisade Bio Reports $2.23 Million Net Loss, Focuses on PALI-2108 Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PALISADE BIO, INC. Palisade Bio Reports $14.4 Million Net Loss for 2024, Highlights Key Developments in Drug Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PALISADE BIO, INC. Palisade Bio Reports Mixed Financial Results, Net Loss, and Strategic Moves in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments